BML‐190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates

@article{New2003BML190AA,
  title={BML‐190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates},
  author={David C. New and Yung H. Wong},
  journal={FEBS Letters},
  year={2003},
  volume={536}
}
  • D. New, Y. Wong
  • Published 11 February 2003
  • Biology, Chemistry
  • FEBS Letters
Modulation of P‐glycoprotein activity by cannabinoid molecules in HK‐2 renal cells
TLDR
The present data provide the first evidence that the endocannabinoid AEA and different synthetic cannabinoids may inhibit the P‐gp activity in vitro via a cannabinoid receptor‐independent mechanism.
Pharmacological actions of cannabinoids.
  • R. Pertwee
  • Biology, Chemistry
    Handbook of experimental pharmacology
  • 2005
TLDR
More information is beginning to emerge about the pharmacological actions of the non-psychoactive plant cannabinoid, cannabidiol, as well as acting on CB1 and CB2 receptors, and there is convincing evidence that anandamide can activate transient receptor potential vanilloid type 1 (TRPV1) receptors.
Tetrahydrocannabinol‐induced neurotoxicity depends on CB1 receptor‐mediated c‐Jun N‐terminal kinase activation in cultured cortical neurons
TLDR
It is reported that THC induces the activation of JNK via the CB1 receptor and its associated G‐protein, Gi/o.n‐terminal kinase, central to the THC‐induced activation of the apoptotic pathway in cortical neurons.
In vitro metabolism of indomethacin morpholinylamide (BML-190), an inverse agonist for the peripheral cannabinoid receptor (CB(2)) in rat liver microsomes.
Functional CB2 type cannabinoid receptors at CNS synapses
Role for Cannabinoid Receptors in Human Proximal Tubular Hypertrophy
TLDR
A role for cannabinoid receptors in proximal tubule cells is identified which may provide novel therapeutic targets for the treatment of diabetes and obesity.
Expression of functional CB1 cannabinoid receptors in retinoic acid‐differentiated P19 embryonal carcinoma cells
TLDR
The protocol used provides an in vitro model system expressing CB1 cannabinoid receptors at the level of mRNA, protein, and AM251‐sensitive agonist‐induced inhibition of intracellular cyclic AMP accumulation, which may be useful to investigate the developmental regulation, expression and function of neuronal cannabinoid receptors.
...
1
2
3
4
...

References

SHOWING 1-10 OF 26 REFERENCES
Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630
TLDR
It is concluded that AM630 is a CB2‐selective ligand that behaves as an inverse agonist at CB2 receptors and as a weak partial agonists at CB1 receptors.
SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist.
TLDR
These data provide evidences for the inverse agonist property of SR 144528 and the constitutive activation of CB2 in Chinese hamster ovary-expressing cells.
Pharmacology of cannabinoid CB1 and CB2 receptors.
  • R. Pertwee
  • Biology, Medicine
    Pharmacology & therapeutics
  • 1997
Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta.
TLDR
One mechanism by which marijuana-derived cannabinoid Delta(9)-tetrahydrocannabinol contributes to immune suppression is by stimulating an enhanced production of lymphocyte TGF-beta, according to the data.
In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor.
TLDR
This is the first report that a CB2-selective inverse agonist, JTE-907, has an anti-inflammatory effect in vivo, and how the inverse agonists showed the same effect as Win55212-2 and Delta(9)-THC is discussed.
Pharmacology of cannabinoid receptor ligands.
  • R. Pertwee
  • Biology, Chemistry
    Current medicinal chemistry
  • 1999
TLDR
This review summarizes current knowledge about the in vitro pharmacological properties of important CB1 and CB2 receptor ligands and pays particular attention to the binding properties of these ligands, to the efficacies of cannabinoid receptor agonists, as determined using cyclic AMP or [35S]GTPgammaS binding assays, and to selected examples of how these pharmacological Properties can be influenced by chemical structure.
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
TLDR
It is considered premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification, because pharmacological evidence for the existence of additional types of cannabinoid receptor is emerging and other kinds of supporting evidence are still lacking.
Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
TLDR
The results demonstrate that the CB2 receptor is functionally coupled to inhibition of adenylyl cyclase activity via a pertussis toxin-sensitive G protein.
Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling.
  • Q. Tao, M. Abood
  • Biology, Chemistry
    The Journal of pharmacology and experimental therapeutics
  • 1998
TLDR
The data suggest that this aspartate residue is not generally important for ligand recognition in the cannabinoid receptors; however, it is required for communication with G proteins and signal transduction.
...
1
2
3
...